Chiesi SAS

This is an observational, prospective, multicentric, cohort study conducted in France to evaluate the QoL in COPD patients treated with TRIMBOW NEXThaler 88/5/9 in a routine clinical practice setting. Patients enrolled in this study will be patients diagnosed with a COPD with a ratio of post-bronchodilator (salbutamol 400 μg) forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) of less than 0.7 to whom TRIMBOW NEXThaler 88/5/9 has been initiated by an hospital or local pulmonologists in accordance with clinical practice and marketing authorization.

TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).

主要目的：证明CHF1535pMDI治疗COPD患者在肺功能方面（第24周的早晨用药前一秒用力呼气量（FEV1）较基线变化）非劣效于信必可都保。 次要目的：评估CHF1535pMDI对其它肺功能参数和患者报告的结局（PRO）的影响。评估研究治疗的安全性和耐受性。